|
Originally published In Press as doi:10.1074/jbc.M203988200 on May 6, 2002
J. Biol. Chem., Vol. 277, Issue 28, 25277-25282, July 12, 2002
Normalization of Intracellular Ca2+ Induces a
Glucose-responsive State in Glucose-unresponsive -Cells*
Kohtaro
Minami §,
Masaaki
Yokokura ,
Nobuko
Ishizuka , and
Susumu
Seino ¶
From the Department of Cellular and Molecular
Medicine, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba 260-8670, Japan and the § Department
of Medical Genetics (Novo Nordisk Pharma), School of Medicine,
Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba 260-8670, Japan
Received for publication, April 24, 2002
 |
ABSTRACT |
Although intracellular
Ca2+ in pancreatic -cells is the principal
signal for insulin secretion, the effect of chronic elevation of the
intracellular Ca2+ concentration
([Ca2+]i) on insulin secretion is poorly
understood. We recently established two pancreatic -cell MIN6 cell
lines that are glucose-responsive (MIN6-m9) and glucose-unresponsive
(MIN6-m14). In the present study we have determined the cause of the
glucose unresponsiveness in MIN6-m14. Initially, elevated
[Ca2+]i was observed in MIN6-m14, but
normalization of the [Ca2+]i by nifedipine, a
Ca2+ channel blocker, markedly improved the intracellular
Ca2+ response to glucose and the glucose-induced insulin
secretion. The expression of subunits of ATP-sensitive K+
channels and voltage-dependent Ca2+ channels
were increased at both mRNA and protein levels in MIN6-m14 treated
with nifedipine. As a consequence, the functional expression of these
channels at the cell surface, both of which are decreased in MIN6-m14
without nifedipine treatment, were increased significantly. Contrariwise, Bay K8644, a Ca2+ channel agonist, caused
severe impairment of glucose-induced insulin secretion in
glucose-responsive MIN6-m9 due to decreased expression of the channel
subunits. Chronically elevated [Ca2+]i,
therefore, is responsible for the glucose unresponsiveness of MIN6-m14.
The present study also suggests normalization of [Ca2+]i in pancreatic -cells as a therapeutic
strategy in treatment of impaired insulin secretion.
 |
INTRODUCTION |
Because intracellular Ca2+ is involved in a variety of
cellular processes such as signal transduction, gene expression, and hormone release (1-6), disturbed intracellular Ca2+
homeostasis readily induces cell dysfunction (7, 8). In pancreatic
-cells, a rise in the intracellular Ca2+ concentration
([Ca2+]i) is the trigger for insulin secretion.
As the extracellular glucose concentration increases, intracellular ATP
is increased and the ATP-sensitive K+ (KATP)
channels are closed, depolarizing the plasma membrane and opening the
voltage-dependent Ca2+ channels
(VDCCs),1 which allows
Ca2+ influx. The rise in [Ca2+]i in
the -cells triggers exocytosis of the insulin granules (9). When the
blood glucose level falls, [Ca2+]i returns to
basal level. In this context, persistent hyperglycemia might well cause
sustained elevated [Ca2+]i and abnormalities in
glucose-induced insulin secretion. It has been reported that human
pancreatic islets cultured with high glucose show elevated basal
[Ca2+]i together with loss of the glucose-induced
rise in [Ca2+]i and glucose-induced insulin
secretion (10). Normal pancreatic -cells exposed to high glucose
exhibit an abnormal response of intracellular Ca2+ and
impaired insulin secretion (11), impairments which also are observed in
the -cells of diabetic animals (12-14). However, the molecular
basis of the effect of chronic elevation of
[Ca2+]i on insulin secretion has not been
examined in detail, primarily because an appropriate in
vitro model has not been available.
We recently established two pancreatic -cell lines with contrary
features, glucose-responsive (MIN6-m9) and glucose-unresponsive (MIN6-m14), and have shown these cell lines to be useful in -cell studies (15). MIN6-m9 exhibit glucose metabolism and insulin secretion
similar to normal pancreatic -cells, while MIN6-m14 exhibit
abnormalities in glucose metabolism, KATP channel activity, VDCC activity, and glucose-induced insulin secretion (15).
In the present study we have determined the factors responsible for the
glucose-unresponsiveness in MIN6-m14. [Ca2+]i in
MIN6-m14 is significantly higher than in MIN6-m9. When the
[Ca2+]i level was normalized by nifedipine, a
Ca2+ channel blocker, the glucose-induced insulin secretion
was increased dramatically in MIN6-m14 with a concomitant improvement
of KATP channel and VDCC activities. Accordingly,
chronically elevated [Ca2+]i is the major factor
contributing to the defect in glucose responsiveness of MIN6-m14, and
normalization of [Ca2+]i restores the
glucose-responsive state of the cells. Because abnormalities of
[Ca2+]i in pancreatic -cells are associated
with chronic exposure to high glucose in both normal and diabetic
animals (8, 10-14), the present study suggests normalization of
[Ca2+]i as a therapeutic strategy for the glucose
unresponsiveness of -cells in type 2 diabetic patients.
 |
EXPERIMENTAL PROCEDURES |
Cell Culture and Measurement of
[Ca2+]i--
MIN6 cells were cultured in
Dulbecco's modified Eagle's medium with 25 mM
glucose supplemented with 10% heat-inactivated fetal calf serum under
humidified condition of 5% CO2/95% air at 37 °C (15).
Cells were loaded with 5 µM fura-2 acetoxymethyl ester (Fura-2 AM) (Dojindo, Kumamoto, Japan) for 1 h in culture medium without pH indicator or in HEPES-balanced Krebs-Ringer bicarbonate buffer (KRH: 119 mM NaCl, 4.74 mM KCl, 2.54 mM CaCl2, 1.19 mM MgCl2, 1.19 mM KH2PO4,
25 mM NaHCO3, and 10 mM HEPES, pH
7.4) containing 0.2% BSA (BSA-KRH) with 0.1 mM glucose.
[Ca2+]i was measured by a dual-excitation
wavelength method (340/380 nm) with a fluorometer (Fluoroskan Ascent
CF; Labsystems, Helsinki, Finland). [Ca2+]i was
calibrated using solutions containing known Ca2+
concentrations (Molecular Probes, Eugene, OR).
Measurement of Insulin Secretion--
Cells (1 × 105 cells/well, 48-well plate) were exposed to 10 µM nifedipine (Sigma), 300 µM
diazoxide (Sigma), or 1 µM Bay K8644 (Sigma) for 24 h (preculture). All media contained 0.1% Me2SO. The cells
were then washed with BSA-KRH and preincubated for 30 min in the same
buffer containing 1 mM glucose. Incubation was performed
with various concentrations of glucose with or without other agents as
indicated for 1 h at 37 °C. The drugs used in preculture were
omitted throughout the secretion experiments. Released insulin was
measured as described previously (15). The amounts of insulin secretion
were normalized by the cellular insulin contents determined by
acid-ethanol extraction.
Assay for Enzyme Activities--
For determination of
glucose-phosphorylating activity, disrupted cells were centrifuged, and
supernatants were incubated in a triethanolamine buffer, pH 7.4, containing 0.5 mM NADP, 5 mM ATP, 1 unit/ml
glucose-6-phosphate dehydrogenase, and 0.5 or 50 mM glucose
at 30 °C. Velocity of NADPH formation was monitored by reading
absorbencies at 340 nm. Enzyme activity was expressed as nmol
NADPH/min/mg of protein (15). Activity of lactate dehydrogenase (LDH)
was determined as follows: briefly, cell extracts were incubated in a
glycylglycine buffer, pH 10.0, with 1 mM lactate, 5 mM NAD, 50 mM glutamate, and 10 unit/ml
glutamate-pyruvate transaminase at 25 °C. Velocity of NADH formation
was monitored by reading absorbencies at 340 nm. Enzyme activity is
expressed as nmol NADH/min/mg of protein (15).
Determination of ATP Production--
For measurement of ATP
production, cells were incubated for 1 h in the presence or
absence of 25 mM glucose. The cells then were washed twice
with ice-cold PBS and solubilized, and the amount of ATP was measured
with an ATP bioluminescent assay kit (Roche Molecular Diagnostics,
Mannheim, Germany), according to the manufacturer's instruction.
Electrophysiological Analyses--
Whole cell recordings of
ATP-sensitive K+ current were performed as described
previously (15). The extracellular solution contained 135 mM NaCl, 5 mM KCl, 5 mM
CaCl2, 2 mM MgSO4, 5 mM HEPES, and 3 mM glucose, pH 7.4. The pipette solution
contained 107 mM KCl, 11 mM EGTA, 2 mM MgSO4, 1 mM CaCl2,
and 11 mM HEPES, pH 7.2. Whole cell Ba2+
currents through the VDCCs were recorded as described (15). Briefly,
Ba2+ was used as a charged carrier for measurement of VDCC
currents. The extracellular solution contained 40 mM
Ba(OH)2, 20 mM 4-aminopyridine, 90 mM tetraethylammonium hydroxide, 10 mM
tetraethylammonium chloride, 140 mM methanesulfonate, and
10 mM MOPS, pH 7.4. The pipette solution contained 10 mM CsCl, 130 mM cesium aspartate, 10 mM EGTA, 5 mM Mg-ATP, and 10 mM
MOPS (pH 7.2). Cells were maintained at a holding potential of 60 mV,
and square pulses of 400-msec duration at potentials between 40 and
+70 mV in steps of 10-mV were applied every 4 s. Recordings were
made using the EPC-7 amplifier (List Electronics, Darmstadt, Germany).
RNA Blotting--
Total RNA (10 µg) from cells was subjected
to formaldehyde-agarose gel electrophoresis. RNA was transferred to a
nylon membrane and UV-cross-linked. Membrane was hybridized with
-[32P]dCTP-labeled probes corresponding to the
cDNA of mouse hexokinase-I (HK-I) (GenBankTM accession
no. J05277, nt 1464-1903), mouse glucokianse (GK) (L38990, nt
98-652), mouse lactate dehydrogenase-A (LDH-A) (NM_010699, nt
291-980), mouse Kir6.2 (U73626, nt 753-1427), hamster sulfonylurea
receptor 1 (SUR1) (L40623, nt 3126-4049), mouse
1-subunit of VDCC (NM_009781, nt 4889-5446), or mouse
3-subunit of VDCC (NM_007581, nt 801-1600). Rediprime
random primer labeling kit (Amersham Biosciences) was used to label the
probes. Blots were exposed to Kodak X-OMAT AR film (Eastman Kodak Co.,
Rochester, NY) at 80 °C.
Subcellular Fractionation and Immunoblotting--
Cells were
scraped into a lysis buffer termed buffer A, containing 150 mM NaCl, 50 mM Tris, pH 7.4, 1 mM
EDTA, 1 mM EGTA, and 1 mM dithiothreitol with
protease inhibitors and sonicated (TOMY Sonicator UD201; Tomy,
Tokyo, Japan; 1 × 10-s burst; output power = 1)
and then centrifuged at 700 × g for 15 min. The
pellet, which contained nuclei and undisrupted cells, was discarded.
The supernatant was centrifuged at 8000 × g for 15 min. The 8,000 × g pellet was referred to as the
plasma membrane-enriched fraction. The supernatant was then
ultracentrifuged at 100,000 × g for 1 h. The
pellet was enriched in internal membranes. The final supernatant obtained was the cytosolic fraction. All fractions were resuspended in
the same volume of buffer A with 1% Triton X-100. Aliquots from each
subcellular fraction (volumes equal to PM fractions containing 5 µg
of protein) were subjected to SDS-PAGE. Resolved proteins were
transferred to polyvinylidene fluoride membranes (Millipore, Bedford,
MA) and probed with antibodies against Kir6.2 (16), SUR1 (17), the
1-subunit of VDCCs (Alomone, Jerusalem, Israel), or the
3-subunit of VDCCs (Alomone). Secondary antibodies were
conjugated to horseradish peroxidase and visualized by enhanced chemiluminescence reagent (Amersham Biosciences). Kir6.2 was detected as a multimeric complex with SUR1 because it was difficult to denature
completely. Mobility of the complex on the gel was determined by
Kir6.2/SUR1-co-transfected Ltk cell extracts. Blots were quantified by
scanning densitometry (Amersham Biosciences). To verify subcellular fractionation, Na+/K+-ATPase (Upstate
Biotechnology, Lake Placid, NY) and sarco/endoplasmic reticulum
Ca2+-ATPase (Santa Cruz Biotechnology, Santa Cruz, CA),
markers for plasma membrane and internal membrane, respectively,
were detected by immunoblotting.
Statistical Analysis--
Values are expressed as means ± S.E. The significance of differences between test groups was evaluated
by unpaired Student's t test or one-way analysis of
variance followed by Tukey's test. p < 0.05 was
considered significant.
 |
RESULTS |
[Ca2+]i of MIN6-m9 and MIN6-m14--
In
the standard culture condition (Dulbecco's modified Eagle's medium
with 10% fetal calf serum and 25 mM glucose),
[Ca2+]i in MIN6-m14 (317 ± 7 nM, n = 8) was significantly higher than in
MIN6-m9 (227 ± 4 nM, n = 8) (Fig.
1A). Application of the
Ca2+ channel blocker nifedipine (10 µM for
24 h) lowered [Ca2+]i of MIN6-m14 to levels
similar to those in MIN6-m9 (Fig. 1A). Intracellular
Ca2+ was poorly responsive to glucose in control MIN6-m14
(without nifedipine treatment), but the response was markedly improved in nifedipine-treated MIN6-m14 (Fig. 1B).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 1.
Intracellular Ca2+ concentration
([Ca2+]i) in MIN6 cells.
A, [Ca2+]i in standard culture
condition. Cells (1 × 105 cells/well, 96-well plate)
were treated with or without 10 µM nifedipine. The cells
were loaded with 5 µM Fura-2 AM, and
[Ca2+]i was measured in the culture medium
without a pH indicator. n = 8, **, p < 0.01. m9, MIN6-m9, m14, MIN6-m14,
m14-Nif, nifedipine-treated MIN6-m14. B,
[Ca2+]i change in response to glucose. Cells were
treated with or without 10 µM nifedipine and loaded with
5 µM Fura-2 AM. [Ca2+]i was
measured in BSA-KRH with 0.1 mM glucose at 30-s intervals,
and 25 mM glucose (final concentration) was added to each
well at the indicated time points. m14, MIN6-m14,
m14-Nif, nifedipine-treated MIN6-m14. n = 6.
|
|
Insulin Secretion before and after Normalization of
[Ca2+]i--
Although normalization of
[Ca2+]i by nifedipine did not alter basal levels
of insulin secretion in MIN6-m14, glucose-induced insulin secretion was
dramatically increased after normalization of
[Ca2+]i (Fig.
2A). Because the cellular
insulin content also was increased by nifedipine (226.2 ± 4.2 versus 505.2 ± 12 pmol/mg of protein,
n = 4; control MIN6-m14 versus nifedipine
treated-MIN6-m14), insulin secretion was normalized by the contents.
The insulin secretion at 25 mM glucose was 20.8 ± 1.1 and 121.4 ± 10.9 pmol/h/mg of protein in control MIN6-m14 and
nifedipine-treated MIN6-m14, respectively. The nifedipine was washed
out before the secretion experiments and was omitted thereafter
throughout the experiments. These results indicate that the
normalization of [Ca2+]i restored the glucose
responsiveness of MIN6-m14 both in intracellular Ca2+ and
insulin secretion.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 2.
Insulin secretory response in MIN6-m14 before
and after normalization of
[Ca2+]i by nifedipine. Cells
(1 × 105 cells/well, 48-well plate) were treated with
or without 10 µM nifedipine for 24 h. The cells were
washed and pre-incubated for 30 min at 37 °C in BSA-KRH containing 1 mM glucose without nifedipine. Incubation was performed in
BSA-KRH with indicated concentrations of glucose (A),
glibenclamide (B), or Bay K8644 (C) for 1 h
at 37 °C. Note that nifedipine was absent throughout the secretion
experiment. Values of secreted insulin were normalized by cellular
insulin contents. m14, MIN6-m14; m14-Nif,
nifedipine-treated MIN6-m14. n = 4, *,
p < 0.05, and **, p < 0.01.
|
|
Glibenclamide- and Bay K8644-stimulated Insulin Secretion--
We
then examined the effects of normalization of
[Ca2+]i on glibenclamide- or Bay K8644-stimulated
insulin secretion. Glibenclamide, a sulfonylurea, stimulates insulin
secretion by inhibiting the KATP channels (18), while Bay
K8644 stimulates insulin secretion by activating the VDCCs of
pancreatic -cells (19). Neither glibenclamide (1 µM)
nor Bay K8644 (1 µM) had a significant stimulatory effect
on insulin secretion in control MIN6-m14, but effects were observed
when [Ca2+]i was normalized by nifedipine (Fig.
2, B and C). These results suggest that
normalization of [Ca2+]i by nifedipine treatment
improves the function of the KATP channels and/or the
VDCCs, both of which are impaired in control MIN6-m14 (15).
Effects of Normalization of [Ca2+]i on
Glucose Metabolism in MIN6-m14--
To evaluate the effect of
normalization of [Ca2+]i by nifedipine on glucose
metabolism in MIN6-m14, we measured activity of enzymes involved in
glucose metabolism and ATP production. Differently than in normal
-cells, glucose-phosphorylating activity in MIN6-m14 is due mostly
to HK, a low Km isoform of the
glucose-phosphorylating enzyme (15). Normalization of
[Ca2+]i by nifedipine did not alter either HK or
GK activity (Fig. 3A). Lactate
dehydrogenase activity, which is increased in control MIN6-m14 as
compared with MIN6-m9 (14), was not altered by nifedipine (Fig.
3B). Furthermore, normalization of
[Ca2+]i had no influence on ATP production in
MIN6-m14 (Fig. 3C). These results demonstrate that
normalization of [Ca2+]i by nifedipine does not
change glucose metabolism in MIN6-m14.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 3.
Enzyme activities and ATP production.
A, glucose phosphorylating activity. Cells were grown on a
culture dish (10-cm diameter) with or without 10 µM
nifedipine for 24 h. The cells were lysed and incubated in a
buffer containing 0.5 mM NADP, 5 mM ATP,
1 unit/ml glucose-6-phosphate dehydrogenase, and 0.5 or 50 mM glucose at 30 °C. Enzyme activity is expressed as
nmol of NADPH/min/mg of protein. Glucose phosphorylating activity at
0.5 mM glucose represents HK activity, and GK activity is
the activity at 50 mM glucose minus that at 0.5 mM glucose. B, LDH activity. Cells (1 × 105 cells/well, 48-well plate) were treated with or without
10 µM nifedipine for 24 h. Cell extracts were
incubated in buffer with 1 mM lactate, 5 mM
NAD, 50 mM glutamate, and 10 unit/ml glutamate-pyruvate
transaminase at 25 °C. Enzyme activity was expressed as nmol of
NADH/min/mg of protein. C, cellular ATP contents. Cells
treated with or without 10 µM nifedipine were incubated
for 1 h in the presence or absence of 25 mM glucose.
The ATP concentration of the cell lysate was measured with an ATP
bioluminescent assay kit. m14, MIN6-m14; m14-Nif,
nifedipine-treated MIN6-m14. n = 4. There was no
significant difference between treatments in all experiments.
|
|
Electrophysiological Analyses of KATP Channels and
VDCCs--
We then performed functional analyses of the
KATP channels and the VDCCs by patch clamp technique.
Normalization of [Ca2+]i by nifedipine
significantly increased KATP channel conductance in
MIN6-m14 (Fig. 4A). In
addition, VDCC currents at the whole cell level also were restored by
normalization of [Ca2+]i by nifedipine. Peak
current was significantly greater in nifedipine-treated MIN6-m14 than
in control MIN6-m14 (Fig. 4B). These data show that both
KATP channel and VDCC activities are significantly improved
in MIN6-m14 after normalization of [Ca2+]i.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 4.
Electrophysiology of KATP
channels and VDCCs. A, normalized peak
KATP channel conductance. Cells cultured on collagen-coated
slide glass were treated with or without 10 µM nifedipine
for 24 h and then used for recording. Because the membrane area of
each cell varies, the ATP-sensitive conductance was normalized by
dividing by the membrane capacitance for each cell. m14,
MIN6-m14; m14-Nif, nifedipine-treated MIN6-m14.
n = 7-9, *, p < 0.05. B,
current-voltage relationships of VDCCs. Whole-cell Ba2+
currents through VDCCs were recorded. m14, MIN6-m14;
m14-Nif, nifedipine-treated MIN6-m14. n = 19-22. **, p < 0.01.
|
|
Expressions of Various Genes Important in Glucose-induced Insulin
Secretion--
Normalization of [Ca2+]i by
nifedipine did not alter mRNA expression of either GK or HK (Fig.
5A). mRNA levels of LDH were decreased after normalization of [Ca2+]i
(Fig. 5A). mRNA expression of Kir6.2, the pore-forming subunit of the -cell KATP channel, was markedly
increased by treatment with nifedipine (Fig. 5B). SUR1, the
regulatory subunit of KATP channels, showed a slight
increase in mRNA levels (Fig. 5B). Expression of the
1-subunit of the VDCCs was increased strongly in
MIN6-m14 after normalization of [Ca2+]i, but
there was no significant difference in mRNA expression of the
3-subunit of VDCCs (Fig. 5B).

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 5.
RNA blotting of molecules involved in glucose
metabolism (A) and KATP channels
and VDCCs (B). Total RNA was isolated from
MIN6-m14 treated with or without 10 µM nifedipine for
24 h, and 10 µg of aliquot was electrophoresed and transferred
onto a nylon membrane. The membrane was probed with
32P-labeled DNA fragments corresponding to cDNA
indicated in the figure. Photographs of 18 S RNA are shown to confirm
equal loading. m14, MIN6-m14; m14-Nif,
nifedipine-treated MIN6-m14.
|
|
Subcellular Localization of the Subunits of KATP
Channels and VDCCs--
We investigated the subcellular localization
of subunits of KATP channels and VDCCs before and after
normalization of [Ca2+]i. Subcellular
fractionation was verified by immunoblot analysis of
Na+/K+-ATPase and sarco/endoplasmic reticulum
Ca2+-ATPase, markers for plasma membrane and internal
membrane fractions, respectively. Normalization of
[Ca2+]i by nifedipine increased the levels of
Kir6.2 in both plasma membrane and internal membrane fractions
significantly to a similar degree (Fig.
6B). SUR1 was somewhat
increased by treatment with nifedipine, but the differences were small
(Fig. 6C). Expression level of the 1-subunit
of VDCCs was increased significantly both in plasma membrane and
internal membrane fractions of MIN6-m14 after normalization of
[Ca2+]i (Fig. 6D), while the
expression level of the 3-subunit was unaffected by
nifedipine (Fig. 6E). These results indicate that the Kir6.2
subunit of KATP channels and the 1-subunit
of VDCCs are increased at the protein level, while membrane trafficking of these channel subunits is not affected by
[Ca2+]i.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 6.
Immunoblotting of the subunits of
KATP channels and VDCCs in subcellular fractions.
Cells treated with or without 10 µM nifedipine were
fractionated into plasma membrane-enriched fraction (PM),
internal membrane-enriched fraction (IM), and cytosol
fraction (Cyt). Aliquots of each fraction (5 µg of protein
equivalent to PM fraction) were subjected to SDS-PAGE, and
blots were probed with antibodies indicated in the figures.
A, verification of specificity for subcellular components.
Antibodies to Na+/K+-ATPase to
sarco/endoplasmic reticulum Ca2+-ATPase were used as
markers for plasma and internal membranes, respectively.
B-E, quantification of KATP channel
(B, Kir6.2; and C, SUR1) and VDCC (D,
1- and E, 3-) subunit
proteins. Data form four separate experiments are illustrated,
normalized to the intensity of the signals of PM fractions (arbitrary
units; means ± S.E.). Photographs are representative results.
m14, MIN6-m14; m14-Nif, nifedipine-treated
MIN6-m14. *, p < 0.05, **, p < 0.01.
|
|
Effects of Other Ca2+ Modulating Agents on MIN6-m14 and
MIN6-m9 Cells--
To confirm that the improved glucose responsiveness
in MIN6-m14 after nifedipine treatment was due to the normalization of [Ca2+]i, we measured the effect of diazoxide,
which activates the KATP channel and hyperpolarizes the
plasma membrane, thereby inhibiting Ca2+ influx through the
VDCCs (20). Pre-exposure of MIN6-m14 to diazoxide (300 µM
for 24 h) normalized [Ca2+]i and restored
the Ca2+ response to glucose (Fig.
7B). At the same time, the
glucose-induced insulin secretion also was significantly improved (Fig.
7A). Expressions of the Kir6.2 and the
1-subunit were increased significantly by diazoxide in
both plasma membrane and internal membrane fractions in MIN6-m14 (Fig.
7C). We also examined the effects of Bay K8644 (1 µM), a Ca2+ channel agonist, in
glucose-responsive MIN6-m9. Bay K8644 increased [Ca2+]i in MIN6-m9 (227 ± 4 and 339 ± 2 nM, n = 6, before and after application
of Bay K8644, respectively). Glucose-induced insulin secretion, as well
as the Ca2+ response to glucose, was severely impaired
after treatment with Bay K8644 in MIN6-m9 (Fig. 7, D and E).
Expressions of both the Kir6.2 and the 1-subunits were
decreased by Bay K 8644 (Fig. 7F). These data suggest that
chronically high [Ca2+]i impairs glucose
responsiveness in MIN6 cells by decreasing the expression of both
KATP channels and VDCCs.

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 7.
Effects of diazoxide in MIN6-m14cells
(A-C) and Bay K8644 in MIN6-m9 cells (D-F).
MIN6-m14 cells (A-C) and MIN6-m9 cells (D-F)
were treated with and without 300 µM diazoxide
(A-C) or 1 µM Bay K8644 (D-F) for
24 h. A and D, glucose-induced insulin
secretion. n = 4, *, p < 0.05, **,
p < 0.01. B and E,
[Ca2+]i change in response to glucose.
C, F, immunoblotting of Kir6.2 and
1-subunits in different subcellular fractions.
m14, MIN6-m14; m14-Dzx, diazoxide-treated
MIN6-m14; and m9. MIN6-m9, m9-Bay K; Bay
K8644-treated MIN6-m9.
|
|
 |
DISCUSSION |
We used two clonal pancreatic -cell lines, MIN6-m9 and
MIN6-m14, in the present study as models of glucose-responsive and glucose-unresponsive -cells, respectively. We previously
demonstrated decreased activities of KATP channels and
VDCCs in glucose-unresponsive MIN6-m14 (15). KATP channels
and VDCCs serve a crucial role in coupling glucose metabolism to
exocytosis of the insulin granules in pancreatic -cells (18). Here
we show that MIN6-m14 exhibit elevated [Ca2+]i
compared with glucose-responsive MIN6-m9, and that normalization of
[Ca2+]i by the Ca2+ channel blocker
nifedipine restores the activities of both KATP channels
and VDCCs to repair glucose-induced insulin secretion in MIN6-m14. It
should be noted that normalization of [Ca2+]i
also was achieved by the KATP channel opener diazoxide with
effects similar to those of nifedipine. Moreover, the Ca2+
channel agonist Bay K8644 exerted effects contrary to the channel blocker in glucose-responsive MIN6-m9. These findings confirm that
chronically elevated [Ca2+]i is the major cause
of the glucose unresponsiveness in MIN6-m14.
The activities of KATP channels and VDCCs can be regulated
by various factors, including gene expression,
phosphorylation/dephosphorylation, and trafficking to the plasma
membrane (21-36). Our data show that normalization of
[Ca2+]i increases the expression of both
KATP channels and VDCCs. In particular, Kir6.2, the
pore-forming subunit of the KATP channels of pancreatic
-cells (23), and the 1-subunit of the VDCCs, also the
pore-forming subunit of the channel (24), were strongly up-regulated at
both the mRNA (Fig. 5) and protein levels (Fig. 6). Contrariwise,
Bay K8644, a Ca2+ channel agonist, decreased the expression
of the Kir6.2 subunit of KATP channels and the
1-subunit of VDCCs (Fig. 7F). Little is known
of the regulation of these channel expressions, but it has been
reported that high glucose leads to marked decreases in both Kir6.2 and
SUR1 expression in isolated rat pancreatic islets as well as in the
INS-1 -cell line (25). A decrease in Kir6.2 expression also has been
noted in pancreatic islets of Zucker diabetic fatty rats (26).
Furthermore, mRNA expression of the - and -subunits of VDCCs
are down-regulated in high glucose-infused rats, but diazoxide restores
expression (27, 28). mRNA levels of the 1-subunit of
VDCCs also are reduced in pancreatic -cells of Zucker diabetic fatty
rats (29). Because persistent hyperglycemia causes sustained elevation
of [Ca2+]i in the -cells (8, 10), these
observations may well be the result of alteration in
[Ca2+]i. Considering these findings together,
[Ca2+]i most likely regulates the expression of
KATP channels and VDCCs at the transcriptional level. It
recently has been shown that intracellular membrane trafficking of ion
channel subunits is important in the functional expression of these
channels at the cell surface (30-37). To evaluate the effect of
intracellular Ca2+ on membrane trafficking of the channels,
we measured the protein levels of the channel subunits in different
subcellular fractions. However, the relative abundance of the
KATP channel subunits and the VDCC subunits in plasma
membrane fraction and internal membrane fraction was similar in
MIN6-m14 before and after nifedipine treatment, indicating that
membrane trafficking of these channel subunits is not affected by
[Ca2+]i.
MIN6-m14 exhibit abnormalities not only in glucose responsiveness but
also in glucose sensitivity. As in normal pancreatic islets,
half-maximal insulin secretion occurs at 15 mM glucose in
MIN6-m9, while the value is below 1 mM in MIN6-m14 cells
(15). Although glucose responsiveness (intracellular Ca2+
response to glucose and amount of secreted insulin) was dramatically improved by normalization of [Ca2+]i, glucose
sensitivity remained unchanged (Figs. 2A and 7A).
GK is a rate-limiting enzyme in glycolysis in -cells and is thought
to be a glucose sensor for glucose-induced insulin secretion (38, 39)
because it has a Km value higher than the
physiological concentration of glucose. However, MIN6-m14 predominantly
expresses HK-I, a low Km isoform of the glucose-phosphorylating enzyme, and > 90% of the activity occurs at 0.5 mM of glucose (15), which might well lead to
abnormal glucose sensitivity. Normalization of
[Ca2+]i did not alter the expression of two
isoforms of the enzyme (Fig. 5) or their activities (Fig.
3A), which might account for the unchanged glucose
sensitivity of MIN6-m14 before and after normalization of
[Ca2+]i by nifedipine. Taken together with the
findings on LDH activity and ATP production in MIN6-m14 cells, glucose
metabolism apparently is not influenced by changes in
[Ca2+]i and is regulated independently of
KATP channel and VDCC activities.
In conclusion, chronically elevated [Ca2+]i
induces glucose unresponsiveness in MIN6-m14 by decreasing the
expression of both KATP channels and VDCCs at the protein
level. Normalization of [Ca2+]i by nifedipine or
diazoxide induces a glucose-responsive state from a
glucose-unresponsive state by restoring the functional expressions of
these channels. Since abrogation of intracellular Ca2+
homeostasis in pancreatic -cells has been shown to be associated with impaired insulin secretion (8, 10-13), the present study suggests
normalization of [Ca2+]i in pancreatic -cells
as a therapeutic strategy in the treatment of the impaired
glucose-induced insulin secretion seen in type 2 diabetes.
 |
FOOTNOTES |
*
This work was supported by Grants-in-Aid for Creative
Scientific Research 10NP0201 and for Scientific Research from the
Ministry of Education, Culture, Sports, Science and Technology; by a
scientific research grant from the Ministry of Health, Labour, and
Welfare, Japan; and by grants from Novo Nordisk Pharma Ltd., from
Takeda Chemical Industries Ltd., and from the Yamanouchi Foundation for Research on Metabolic Disorders.The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed. Tel.:
81-43-226-2187; Fax: 81-43-221-7803; E-mail:
seino@med.m.chiba-u.ac.jp.
Published, JBC Papers in Press, May 6, 2002, DOI 10.1074/jbc.M203988200
 |
ABBREVIATIONS |
The abbreviations used are:
VDCC, voltage-dependent Ca2+ channel;
KRH, Krebs-Ringer HEPES;
BSA, bovine serum albumin;
LDH, lactate
dehydrogenase;
MOPS, 4-morpholinepropanesulfonic acid;
HK, hexokinase;
GK, glucokinase;
nt, nucleotide;
PM, plasma membrane.
 |
REFERENCES |
| 1.
|
Ghosh, A.,
and Greenberg, M. E.
(1995)
Science
268,
239-247[Abstract/Free Full Text]
|
| 2.
|
Berridge, M. J.
(1994)
Mol. Cell. Endocrinol.
98,
119-124[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Bito, H.,
Deisseroth, K.,
and Tsien, R. W.
(1997)
Curr. Opin. Neurobiol.
7,
419-429[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Hardingham, G. E.,
and Bading, H.
(1999)
Microsc. Res. Tech.
46,
348-355[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Wollheim, C. B.,
and Sharp, G. W.
(1981)
Physiol. Rev.
61,
914-973[Free Full Text]
|
| 6.
|
Artalejo, C. R.,
Adams, M. E.,
and Fox, A. P.
(1994)
Nature
367,
72-76[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Verkhratsky, A.,
and Toescu, E. C.
(1998)
Trends. Neurosci.
21,
2-7[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Levy, J.
(1999)
Endocrine
10,
1-6[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Prentki, M.
(1996)
Eur. J. Endocrinol.
134,
272-286[Abstract/Free Full Text]
|
| 10.
|
Bjorklund, A.,
Lansner, A.,
and Grill, V. E.
(2000)
Diabetes
49,
1840-1848[Abstract]
|
| 11.
|
Okamoto, Y.,
Ishida, H.,
Taminato, T.,
Tsuji, K.,
Kurose, T.,
Tsuura, Y.,
Kato, S.,
Imura, H.,
and Seino, Y.
(1992)
Diabetes
41,
1555-1561[Abstract]
|
| 12.
|
Tsuji, K.,
Taminato, T.,
Ishida, H.,
Okamoto, Y.,
Tsuura, Y.,
Kato, S.,
Kurose, T.,
Okada, Y.,
Imura, H.,
and Seino, Y.
(1993)
Metabolism
42,
1424-1428[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Kato, S.,
Ishida, H.,
Tsuura, Y.,
Tsuji, K.,
Nishimura, M.,
Horie, M.,
Taminato, T.,
Ikehara, S.,
Odaka, H.,
Ikeda, I.,
Okada, Y.,
and Seino, Y.
(1996)
J. Clin. Invest.
97,
2417-2425[Medline]
[Order article via Infotrieve]
|
| 14.
|
Roe, M. W.,
Philipson, L. H.,
Frangakis, C. J.,
Kuznetsov, A.,
Mertz, R. J.,
Lancaster, M. E.,
Spencer, B.,
Worley, J. F., 3rd,
and Dukes, I. D.
(1994)
J. Biol. Chem.
269,
18279-18282[Abstract/Free Full Text]
|
| 15.
|
Minami, K.,
Yano, H.,
Miki, T.,
Nagashima, K.,
Wang, C. Z.,
Tanaka, H.,
Miyazaki, J. I.,
and Seino, S.
(2000)
Am. J. Physiol.
279,
E773-E781
|
| 16.
|
Suzuki, M.,
Fujikura, K.,
Inagaki, N.,
Seino, S.,
and Takata, K.
(1997)
Diabetes
46,
1440-1444[Abstract]
|
| 17.
|
Kawaki, J.,
Nagashima, K.,
Tanaka, J.,
Miki, T.,
Miyazaki, M.,
Gonoi, T.,
Mitsuhashi, N.,
Nakajima, N.,
Iwanaga, T.,
Yano, H.,
and Seino, S.
(1999)
Diabetes
48,
2001-2006[Abstract]
|
| 18.
|
Seino, S.
(1999)
Annu. Rev. Physiol.
61,
337-362[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Panten, U.,
Zielmann, S.,
Schrader, M. T.,
and Lenzen, S.
(1985)
Naunyn Schmiedebergs Arch. Pharmacol.
328,
351-353[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Malaisse, W. J.,
Pipeleers, D. G.,
and Mahy, M.
(1973)
Diabetologia
9,
1-5[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Inagaki, N.,
Gonoi, T.,
Clement, J. P., 4th,
Namba, N.,
Inazawa, J.,
Gonzalez, G.,
Aguilar-Bryan, L.,
Seino, S.,
and Bryan, J.
(1995)
Science
270,
1166-1170[Abstract/Free Full Text]
|
| 22.
|
Levitan, I. B.
(1994)
Annu. Rev. Physiol.
56,
193-212[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Beguin, P.,
Nagashima, K.,
Nishimura, M.,
Gonoi, T.,
and Seino, S.
(1999)
EMBO J.
18,
4722-4732[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Ertel, E. A.,
Campbell, K. P.,
Harpold, M. M.,
Hofmann, F.,
Mori, Y.,
Perez-Reyes, E.,
Schwartz, A.,
Snutch, T. P.,
Tanabe, T.,
Birnbaumer, L.,
Tsien, R. W.,
and Catterall, W. A.
(2000)
Neuron
25,
533-535[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Moritz, W.,
Leech, C. A.,
Ferrer, J.,
and Habener, J. F.
(2001)
Endocrinology
142,
129-138[Abstract/Free Full Text]
|
| 26.
|
Tokuyama, Y.,
Fan, Z.,
Furuta, H.,
Makielski, J. C.,
Polonsky, K. S.,
Bell, G. I.,
and Yano, H.
(1996)
Biochem. Biophys. Res. Commun.
220,
532-538[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Iwashima, Y.,
Pugh, W.,
Depaoli, A. M.,
Takeda, J.,
Seino, S.,
Bell, G. I.,
and Polonsky, K. S.
(1993)
Diabetes
42,
948-955[Abstract]
|
| 28.
|
Iwashima, Y.,
Abiko, A.,
Ushikubi, F.,
Hata, A.,
Kaku, K.,
Sano, H.,
and Eto, M.
(2001)
Biochem. Biophys. Res. Commun.
280,
923-932[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Tokuyama, Y.,
Sturis, J.,
DePaoli, A. M.,
Takeda, J.,
Stoffel, M.,
Tang, J.,
Sun, X.,
Polonsky, K. S.,
and Bell, G. I.
(1995)
Diabetes
44,
1447-1457[Abstract]
|
| 30.
|
Zerangue, N.,
Schwappach, B.,
Jan, Y. N.,
and Jan, L. Y.
(1999)
Neuron
22,
537-548[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Griffith, L. C.
(2001)
Curr. Biol.
11,
R226-R228[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Gao, T.,
Chien, A. J.,
and Hosey, M. M.
(1999)
J. Biol. Chem.
274,
2137-2144[Abstract/Free Full Text]
|
| 33.
|
Bichet, D.,
Cornet, V.,
Geib, S.,
Carlier, E.,
Volsen, S.,
Hoshi, T.,
Mori, Y.,
and De Waard, M.
(2000)
Neuron
25,
177-1790[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Beguin, P.,
Nagashima, K.,
Gonoi, T.,
Shibasaki, T.,
Takahashi, K.,
Kashima, Y.,
Ozaki, N.,
Geering, K.,
Iwanaga, T.,
and Seino, S.
(2001)
Nature
411,
701-706[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Prince, L. S.,
Workman, R. B., Jr.,
and Marchase, R. B.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
5192-5196[Abstract/Free Full Text]
|
| 36.
|
Ko, Y. H.,
Delannoy, M.,
and Pedersen, P. L.
(1997)
Biochemistry
36,
5053-5064[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Bradbury, N. A.
(1999)
Physiol. Rev.
79,
S175-S191[Medline]
[Order article via Infotrieve]
|
| 38.
|
Newgard, C. B.,
and McGarry, J. D.
(1995)
Annu. Rev. Biochem.
64,
689-719[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Matschinsky, F. M.
(1996)
Diabetes
45,
223-241[Abstract]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S.-N. Yang and P.-O. Berggren
The Role of Voltage-Gated Calcium Channels in Pancreatic {beta}-Cell Physiology and Pathophysiology
Endocr. Rev.,
October 1, 2006;
27(6):
621 - 676.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kawaguchi, K. Minami, K. Nagashima, and S. Seino
Essential Role of Ubiquitin-Proteasome System in Normal Regulation of Insulin Secretion
J. Biol. Chem.,
May 12, 2006;
281(19):
13015 - 13020.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. T. Taylor, L. Huang, B. M. Keyser, H. Zhuang, C. W. Clarkson, and M. Li
Role of high-voltage-activated calcium channels in glucose-regulated {beta}-cell calcium homeostasis and insulin release
Am J Physiol Endocrinol Metab,
November 1, 2005;
289(5):
E900 - E908.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-N. Yang and P.-O. Berggren
{beta}-Cell CaV channel regulation in physiology and pathophysiology
Am J Physiol Endocrinol Metab,
January 1, 2005;
288(1):
E16 - E28.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Nenquin, A. Szollosi, L. Aguilar-Bryan, J. Bryan, and J.-C. Henquin
Both Triggering and Amplifying Pathways Contribute to Fuel-induced Insulin Secretion in the Absence of Sulfonylurea Receptor-1 in Pancreatic {beta}-Cells
J. Biol. Chem.,
July 30, 2004;
279(31):
32316 - 32324.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Huang, A. Bhattacharjee, J. T. Taylor, M. Zhang, B. M. Keyser, L. Marrero, and M. Li
[Ca2+]i regulates trafficking of Cav1.3 ({alpha}1D Ca2+ channel) in insulin-secreting cells
Am J Physiol Cell Physiol,
February 1, 2004;
286(2):
C213 - C221.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
V. Lilla, G. Webb, K. Rickenbach, A. Maturana, D. F. Steiner, P. A. Halban, and J.-C. Irminger
Differential Gene Expression in Well-Regulated and Dysregulated Pancreatic {beta}-Cell (MIN6) Sublines
Endocrinology,
April 1, 2003;
144(4):
1368 - 1379.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|